GlaxoSmithKline Pharmaceuticals Ltd
Ticker: GLAXO
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
2735.70
Market Cap
46344.41
Debt/Equity
0.0051
ROE %
49.751
PB
23.7504
Promoter %
75.000
Pledge %
0.000
1Y Rev Growth %
8.449
5Y Rev Growth %
0.256
NP Margin %
23.785
NP Margin 5Y Avg %
21.156
Trading Reference
1M Return %
-0.765
6M Return %
-4.951
1Y Return %
1.210
% Away 52W High
28.512
% Away 52W Low
42.410
Daily Volume
33150
Investment Verdict
Risky
Score 58/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 21/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
GlaxoSmithKline Pharmaceuticals Ltd is currently trading near a key support level, with the 50-day EMA showing upward momentum. If the stock can maintain above this support, there is a potential for a price increase towards the next resistance level. However, if it falls below the support, it could face significant downside risk.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
A
Anthem Biosciences Ltd
Anthem Biosciences Ltd shows potential but faces challenges in growth consistency and profitability metrics.
View details
V
Voltas Ltd
Voltas Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
B
Balkrishna Industries Ltd
Balkrishna Industries Ltd shows a decent investment potential with strong fundamentals, but caution is advised due to valuation concerns and execution risks.
View details
H
Hexaware Technologies Ltd
Hexaware Technologies has a decent outlook with growth potential, but faces challenges in profitability and valuation metrics.
View details
T
Tata Communications Ltd
Tata Communications Ltd shows potential for growth but faces challenges in profitability and execution risks. It is a decent investment but requires careful monitoring.
View details
C
Cochin Shipyard Ltd
Cochin Shipyard Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
D
Dalmia Bharat Ltd
Dalmia Bharat Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
L
L&T Technology Services Ltd
L&T Technology Services Ltd shows decent potential with a strong focus on digital transformation, but faces challenges in profitability and valuation compared to peers.
View details
H
Housing and Urban Development Corporation Ltd
The stock presents a decent investment opportunity but comes with notable risks and challenges.
View details
3
360 One Wam Ltd
360 One Wam Ltd shows a decent investment potential with consistent growth and a strong business model, but some risks in execution and valuation metrics should be considered.
View details
P
Procter & Gamble Hygiene and Health Care Ltd
The company shows potential for growth but faces challenges in profitability and valuation metrics. Investors should be cautious.
View details
C
Container Corporation of India Ltd
Container Corporation of India Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should be cautious.
View details
J
Jubilant Foodworks Ltd
Jubilant Foodworks Ltd shows potential for growth but faces significant challenges in profitability and market competition.
View details
P
Petronet LNG Ltd
Petronet LNG Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
B
Bank of Maharashtra Ltd
Bank of Maharashtra Ltd shows decent fundamentals with moderate growth potential, but faces competitive and execution challenges.
View details
I
Indian Renewable Energy Development Agency Ltd
The stock has potential due to its position in the renewable energy sector, but faces challenges in execution and governance.
View details
Business Overview
GlaxoSmithKline Pharmaceuticals Ltd (GSK) is a leading global healthcare company focused on pharmaceuticals, vaccines, and consumer health products. Catering primarily to the Indian market, GSK is committed to improving patient outcomes through innovative therapies and preventive solutions. With a strong emphasis on research and development, GSK plays a crucial role in addressing healthcare challenges. Its trusted portfolio of medicines and vaccines ensures better health for individuals and communities alike.
- Global leader in healthcare
- Focus on innovative pharmaceuticals and vaccines
- Strong commitment to research and development
- Trusted by healthcare professionals and patients
- Improving health outcomes in India
- Wide range of consumer health products
Investment Thesis
GlaxoSmithKline Pharmaceuticals Ltd stands out due to its strong promoter credibility, robust growth potential in digital services, and attractive valuation compared to its peers. These factors position the company well for sustainable growth and investor returns.
- Strong backing from a reputable promoter group enhances investor confidence.
- Significant growth opportunities in digital health services align with market trends.
- Attractive valuation metrics provide a compelling entry point for investors.
- Diversified product portfolio mitigates risks and supports revenue stability.
- Commitment to R&D ensures continued innovation and competitive advantage.
Opportunity vs Risk
Opportunities
- Strong pipeline of new drugs
- Expanding global market presence
- Potential for strategic partnerships
- Focus on consumer healthcare
- Increasing demand for vaccines
Risks ⚠️
- Regulatory challenges in India
- Competition from generic drugs
- R&D failures impact growth
- Currency fluctuations affect profits
- Pricing pressures in healthcare sector
Peer Perspective
GlaxoSmithKline Pharmaceuticals Ltd trades at a slight premium to peers like Sun Pharmaceutical and Cipla, reflecting its stable margins. A re-rating could occur if it accelerates growth in its specialty portfolio.
Future Outlook
GlaxoSmithKline Pharmaceuticals Ltd is well-positioned for growth, driven by its innovative pipeline and strong market presence, provided it maintains effective execution and cost control measures.
AI FAQs for Retail Users
- Q: What does GlaxoSmithKline Pharmaceuticals Ltd do?A: It develops and manufactures pharmaceuticals, vaccines, and consumer healthcare products.
- Q: Is GlaxoSmithKline a good investment?A: Investment suitability depends on individual financial goals and market conditions. Research is recommended.
- Q: What are the risks of investing in this stock?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical industry.
- Q: How often does GlaxoSmithKline pay dividends?A: Dividends are typically paid quarterly, but this can vary based on company performance.
- Q: Where can I find more information about GlaxoSmithKline?A: Company reports, financial news, and stock analysis websites provide detailed information.
📊 Stock Investment Checklist (100 Points)
GlaxoSmithKline Pharmaceuticals Ltd • Updated: 2025-09-16 21:02:23
-
10BusinessHighPharmaceutical sector is essential and growing, but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighP/E and P/B ratios are higher than industry average.
-
7BalanceHighModerate debt levels, but liquidity is adequate.
-
9GovernanceHighPromoter holding is strong, but some concerns about disclosures.
-
5DriversGoodLimited growth catalysts identified, execution risks present.
-
2TechnicalsLowWeak momentum and liquidity issues observed.
Final Score & Verdict
Score 68 / 100
• Decent
GlaxoSmithKline Pharmaceuticals Ltd shows decent fundamentals but faces challenges in profitability and market sentiment. It is a stable player in a growing sector, but caution is advised due to valuation concerns and execution risks.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 80/100
- Governance: 65/100
- Market Confidence: 72/100